Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Neurochem Res. 2016 Dec 28;42(4):1202–1210. doi: 10.1007/s11064-016-2157-9

Fig. 2.

Fig. 2

Effects of blockade of D1Rs on basal and scopolamine-stimulated ERK1/2 phosphorylation in the rat striatum and mPFC. a Effects of the D1R antagonist SCH23390 on basal and scopolamine-stimulated ERK1/2 phosphorylation in the CPu. b Effects of SCH23390 on basal and scopolamine-stimulated ERK1/2 phosphorylation in the NAc. c Effects of SCH23390 on basal and scopolamine-stimulated ERK1/2 phosphorylation in the mPFC. Representative immunoblots are shown to the left of the quantified data. Note that SCH23390 reduced and blocked basal and scopolamine-stimulated ERK1/2 phosphorylation, respectively, in the CPu, NAc, and mPFC. Rats were treated with an i.p. injection of saline or SCH23390 (SCH, 0.2 mg/kg) 15 min prior to saline or scopolamine (Sco, 5 mg/kg) and were sacrificed 10 min after final agent administration for Western blot analysis. Data are presented as means ± SEM (n = 5 per group). *p < 0.05 versus control (saline + saline). +p < 0.05 versus saline + scopolamine